The abstract is read at the publisher; the summary is JClub's.
In adults with IgA nephropathy, iptacopan slowed the annualized eGFR decline by 3.02 ml/min/1.73 m² per year versus placebo over 24 months.
- Why it matters: Alternative complement pathway overactivation is linked to glomerular inflammation in IgA nephropathy, and there is a need for therapies that preserve kidney function beyond supportive care.
- What they did: In this phase 3 randomized trial (477 patients; 1:1 iptacopan 200 mg twice daily vs placebo), the primary endpoint was the annualized total eGFR slope over 24 months, with kidney-failure events analyzed by time-to-event methods.
- The result: The composite kidney-failure endpoint occurred in 21.4% with iptacopan vs 33.5% with placebo (hazard ratio 0.57; adjusted P=0.003), with adverse events 87.0% vs 89.1% and no deaths.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.